-1753359608905.webp&w=3840&q=75)
2025 NOSCM | Early-stage Hormone Receptor Positive Breast Cancer: Targeting Therapy to Risk Balanced with Toxicity
0% Complete
Course Overview
Dr. Reshma Mahtani highlighted the SOFT and TEXT trials, showing a 3.8% absolute five-year DFS benefit for AI over tamoxifen in premenopausal patients. The NEOCARB study suggested carboplatin may be dispensable in early-stage HER2-positive disease.
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Reshma L. Mahtani, DO
Accreditation
NA
Related Courses
2026 NOSCM | We Should Change Treatment Based on Emerging Mutations in Patients with ER+/HER2- Metastatic Breast Cancer (NO)
0.00 Credits
1 Chapter
Breast
Free
2026 NOSCM | We Should Change Treatment Based on Emerging Mutations in Patients with ER+/HER2- Metastatic Breast Cancer (YES)
0.00 Credits
1 Chapter
Breast
Free